Results for
"[search-keyword]"
Sponsor content
310 result(s) found, displaying 71 to 80
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SAPHNELO anifrolumab 300 mg concentrated injection vial.
-
Prescription medicine registrationActive ingredients: trastuzumab deruxtecan.
-
Australian Public Assessment Report (AusPAR)AusPAR for Evusheld (tixagevimab and cilgavimab) for treatment of adults with COVID-19.
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Prescription medicine decision summaryEvusheld (tixagevimab and cilgavimab) is approved to treat COVID-19
-
Australian Public Assessment Report (AusPAR)AusPAR for SAPHNELO (anifrolumab) as add on treatment of adult patients with moderate to severe, active systemic lupus erythematosus.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENHERTU trastuzumab deruxtecan 100 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BREZTRI AEROSPHERE 160/7.2/5 budesonide 160 mcg/glycopyrronium 7.2 mcg/formoterol fumarate dihydrate 5 mcg per actuation inhalation pMDI.